{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:14:31Z","timestamp":1783538071522,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272789"],"award-info":[{"award-number":["82272789"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82241232"],"award-info":[{"award-number":["82241232"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473346"],"award-info":[{"award-number":["82473346"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Science and Technology Project","award":["202206010141"],"award-info":[{"award-number":["202206010141"]}]},{"name":"Noncommunicable Chronic Diseases National Science and Technology Major Project","award":["2024ZD0519700"],"award-info":[{"award-number":["2024ZD0519700"]}]},{"name":"Guangzhou Science and Technology Bureau Basic and Applied Basic Research Project","award":["SL2022A04J01033"],"award-info":[{"award-number":["SL2022A04J01033"]}]},{"name":"Young Talents Program of Sun Yat-sen University Cancer Center","award":["YTP-SYSUCC-0094"],"award-info":[{"award-number":["YTP-SYSUCC-0094"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06613-0","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:58:27Z","timestamp":1749031107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non\u2013small cell lung cancer"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct05435248","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"umin000006045","registry":"10.18810\/umin-japan"}],"author":[{"given":"Jianhua","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baili","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"7689","key":"6613_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446\u201354.","journal-title":"Nature"},{"issue":"1","key":"6613_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","volume":"41","author":"BC Bade","year":"2020","unstructured":"Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1\u201324.","journal-title":"Clin Chest Med"},{"issue":"3","key":"6613_CR3","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.3390\/curroncol29030150","volume":"29","author":"H Mithoowani","year":"2022","unstructured":"Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: a review for general practitioners in oncology. Curr Oncol. 2022;29(3):1828\u201339.","journal-title":"Curr Oncol"},{"issue":"2","key":"6613_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7888\/juoeh.41.153","volume":"41","author":"K Yoneda","year":"2019","unstructured":"Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Treatment of non-small cell lung cancer with EGFR-mutations. J uoeh. 2019;41(2):153\u201363.","journal-title":"J uoeh"},{"issue":"6","key":"6613_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1177\/1753465816670498","volume":"10","author":"I Sullivan","year":"2016","unstructured":"Sullivan I, Planchard D. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. Ther Adv Respir Dis. 2016;10(6):549\u201365.","journal-title":"Ther Adv Respir Dis"},{"issue":"Suppl 3","key":"6613_CR6","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.21037\/tlcr.2019.04.20","volume":"8","author":"A Martinez-Marti","year":"2019","unstructured":"Martinez-Marti A, Navarro A, Felip E. Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Transl Lung Cancer Res. 2019;8(Suppl 3):S235\u201346.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"6613_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","volume":"15","author":"K Fu","year":"2022","unstructured":"Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15(1):173.","journal-title":"J Hematol Oncol"},{"issue":"5676","key":"6613_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497\u2013500.","journal-title":"Science"},{"issue":"2","key":"6613_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"9","key":"6613_CR10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046\u201361.","journal-title":"Cancer Discov"},{"issue":"9","key":"6613_CR11","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337.","journal-title":"Br J Cancer"},{"issue":"1","key":"6613_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12943-018-0777-1","volume":"17","author":"SG Wu","year":"2018","unstructured":"Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38.","journal-title":"Mol Cancer"},{"key":"6613_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.lungcan.2017.09.005","volume":"113","author":"CK Lee","year":"2017","unstructured":"Lee CK, Kim S, Lee JS, Lee JE, Kim SM, Yang IS, et al. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lung Cancer. 2017;113:106\u201314.","journal-title":"Lung Cancer"},{"key":"6613_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23136936","author":"E Bertoli","year":"2022","unstructured":"Bertoli E, De Carlo E, Del Conte A, Stanzione B, Revelant A, Fassetta K, et al. Acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer: how do we overcome it? Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23136936.","journal-title":"Int J Mol Sci"},{"issue":"75","key":"6613_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75\u201326.","journal-title":"Sci Transl Med"},{"issue":"5","key":"6613_CR16","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, et al. B7\u2013H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. 2021;27(5):1227\u201335.","journal-title":"Clin Cancer Res"},{"key":"6613_CR17","doi-asserted-by":"publisher","first-page":"106057","DOI":"10.1016\/j.bioorg.2022.106057","volume":"128","author":"HY Zhao","year":"2022","unstructured":"Zhao HY, Xi XX, Xin M, Zhang SQ. Overcoming C797S mutation: the challenges and prospects of the fourth-generation EGFR-TKIs. Bioorg Chem. 2022;128:106057.","journal-title":"Bioorg Chem"},{"key":"6613_CR18","doi-asserted-by":"publisher","first-page":"128729","DOI":"10.1016\/j.bmcl.2022.128729","volume":"72","author":"H Fang","year":"2022","unstructured":"Fang H, Wu Y, Xiao Q, He D, Zhou T, Liu W, et al. Design, synthesis and evaluation of the Brigatinib analogues as potent inhibitors against tertiary EGFR mutants (EGFR(del19\/T790M\/C797S) and EGFR(L858R\/T790M\/C797S)). Bioorg Med Chem Lett. 2022;72:128729.","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"6613_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560\u20132.","journal-title":"Nat Med"},{"issue":"1","key":"6613_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Mok T, Wu YL, Han JY, Ahn MJ, Ramalingam SS, et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. 2023;14(1):1071.","journal-title":"Nat Commun"},{"issue":"14","key":"6613_CR21","doi-asserted-by":"publisher","first-page":"9662","DOI":"10.1021\/acs.jmedchem.2c00704","volume":"65","author":"MS Eno","year":"2022","unstructured":"Eno MS, Brubaker JD, Campbell JE, De Savi C, Guzi TJ, Williams BD, et al. Discovery of BLU-945, a reversible, potent, and wild-type-sparing next-generation EGFR mutant inhibitor for treatment-resistant non-small-cell lung cancer. J Med Chem. 2022;65(14):9662\u201377.","journal-title":"J Med Chem"},{"issue":"16","key":"6613_CR22","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1158\/1078-0432.CCR-22-3901","volume":"29","author":"SM Lim","year":"2023","unstructured":"Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, et al. BBT-176, a novel fourth-generation tyrosine kinase inhibitor for osimertinib-resistant EGFR mutations in non-small cell lung cancer. Clin Cancer Res. 2023;29(16):3004\u201316.","journal-title":"Clin Cancer Res"},{"issue":"7605","key":"6613_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","volume":"534","author":"Y Jia","year":"2016","unstructured":"Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129\u201332.","journal-title":"Nature"},{"key":"6613_CR24","doi-asserted-by":"crossref","unstructured":"BDTX-1535 Goes after Osimertinib Resistance. Cancer Discov. 2021;11(12):2952\u20133.","DOI":"10.1158\/2159-8290.CD-NB2021-0395"},{"issue":"6","key":"6613_CR25","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1158\/1538-7445.AM2024-1229","volume":"84","author":"E Dardenne","year":"2024","unstructured":"Dardenne E, O\u2019Connor M, Nilsson M, He J, Yu X, Heymach JV, et al. Abstract 1229: BDTX-1535: a MasterKey EGFR inhibitor targeting classical and non-classical oncogenic driver mutations and the C797S acquired resistance mutation to address the evolving molecular landscape of EGFR mutant NSCLC. Cancer Res. 2024;84(6):1229.","journal-title":"Cancer Res"},{"issue":"16","key":"6613_CR26","doi-asserted-by":"publisher","first-page":"9011","DOI":"10.1200\/JCO.2023.41.16_suppl.9011","volume":"41","author":"YY Elamin","year":"2023","unstructured":"Elamin YY, Nagasaka M, Shum E, Bazhenova L, Camidge DR, Cho BC, et al. BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1\/2 SYMPHONY study. J Clin Oncol. 2023;41(16):9011.","journal-title":"J Clin Oncol"},{"issue":"7","key":"6613_CR27","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu S, Wu L, Jian H, Cheng Y, Wang Q, Fang J, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(7):624\u201336.","journal-title":"Lancet Respir Med"},{"issue":"15","key":"6613_CR28","doi-asserted-by":"publisher","first-page":"9010","DOI":"10.1200\/JCO.2019.37.15_suppl.9010","volume":"37","author":"PA Janne","year":"2019","unstructured":"Janne PA, Yu HA, Johnson ML, Steuer CE, Vigliotti M, Iacobucci C, et al. Safety and preliminary antitumor activity of U3\u20131402: a HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC. J Clin Oncol. 2019;37(15):9010.","journal-title":"J Clin Oncol"},{"issue":"7","key":"6613_CR29","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25(7):901\u201311.","journal-title":"Lancet Oncol"},{"issue":"2","key":"6613_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","volume":"22","author":"F Zhou","year":"2025","unstructured":"Zhou F, Guo H, Xia Y, Le X, Tan DSW, Ramalingam SS, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025;22(2):95\u2013116.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"6613_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","volume":"19","author":"JK Rotow","year":"2024","unstructured":"Rotow JK, Lee JK, Madison RW, Oxnard GR, J\u00e4nne PA, Schrock AB. Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib. J Thorac Oncol. 2024;19(2):227\u201339.","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06613-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06613-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06613-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T09:58:28Z","timestamp":1749031108000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06613-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6613"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06613-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical trial was approved by the Ethics Committee of Sun Yat-sen University Cancer Center (A2021-184\u201301). Informed consent was provided by all recruited subjects prior to the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of individual data was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"W.X., Yan Yang, Z.C., B.S., D.S., X.S. and P.G. are the employees of Hansoh Pharmaceutical Group Co. Ltd., Shanghai, China. Other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"628"}}